MannKind Corp (MNKD) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.57 (-0.28%), Market cap $1.00B, 52-week low–high $2.28 ~ $6.21.
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with intersti
Financial statements, price targets, institutional (13F) holdings and related news for MannKind Corp are updated in real time on BlackAll Trade.
MannKind Corp trades at $3.57 (-0.28%). Real-time quotes and charts are available on BlackAll Trade.
MannKind Corp has a market cap of about $1.00B.
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious u